Search results
Results from the WOW.Com Content Network
Choriocarcinoma of the placenta during pregnancy is preceded by: hydatidiform mole (50% of cases) spontaneous abortion (20% of cases) ectopic pregnancy (2% of cases) normal term pregnancy (20–30% of cases) hyperemesis gravidarum; Rarely, choriocarcinoma occurs in primary locations other than the placenta; very rarely, it occurs in testicles.
OGCTs are relatively difficult to detect and diagnose at an early stage because of the nonspecific histological characteristics. [1] Common symptoms of OGCT are bloating, abdominal distention, ascites, and dyspareunia. [1] OGCT is caused mainly due to the formation of malignant cancer cells in the primordial germ cells of the ovary. [1]
More advanced disease shows more obvious symptoms or signs that can be detected on a physical examination. The uterus may become enlarged or the cancer may spread, causing lower abdominal pain or pelvic cramping. [10] Painful sexual intercourse or painful or difficult urination are less common signs of endometrial cancer. [9]
The blood test, called Galleri, can detect multiple types of cancer early and targets 80% of cancers currently not screened for that result in cancer deaths, Grail CEO Bob Ragu
Gestational choriocarcinoma can happen during and after any type of pregnancy event, though risk of the disease is higher in and after complete or partial molar pregnancies. [3] Risk of disease may also be higher in those experiencing pregnancy at younger or older ages that average, such as below 15 years old or above 45 years old. [4]
Gynecologic cancer is a type of cancer that affects the female reproductive system, including ovarian cancer, uterine cancer, vaginal cancer, cervical cancer, and vulvar cancer. Gynecological cancers comprise 10-15% of women's cancers, mainly affecting women past reproductive age but posing threats to fertility for younger patients. [ 1 ]
Reuters reported on Tuesday that Illumina is expected to get an order from EU antitrust later this week to sell Grail, which develops blood-based early cancer detection tests.
Grail, valued at $7.1 billion under Illumina's deal, is seeking to market a blood test that can diagnose many kinds of cancer, known as a liquid biopsy. Illumina had spun off Grail in 2016 but ...